Celsion Corporation – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
SummaryPharmaceuticals and Healthcare
Key Findings
Pharmaceuticals and Healthcare
Pharmaceuticals and Healthcare
Reasons To Buys
MarketLine
Key Highlights
United States
Celsion is a development stage oncology drug company focused on developing a portfolio of cancer treatments, including directed chemotherapies, deoxyribonucleic acid (DNA)-mediated immunotherapy and ribonucleic acid based therapies. The company's main product candidate is ThermoDox?, a proprietary heat-activated liposomal encapsulation of doxorubicin, in a Phase III clinical trial for the treatment of primary liver cancer. Second in the company's pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian and brain cancers. The company has two platform technologies of therapeutics for difficult-to-treat forms of cancer including: Lysolipid Thermally Sensitive Liposomes and TheraPlas.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.